Radiographic assessment of nocturnal gastric juice secretion after administration of roxatidine acetate hydrochloride.
Adult patients with symptoms of gastric disease were randomly assigned to a treatment group (n = 103) or untreated control group (n = 89). The treatment group received 75 mg of roxatidine acetate hydrochloride at 9 PM and 12 to 13 hours later gastric juice secretion was measured with gastric x-ray films in both groups. Mean gastric juice secretion was significantly lower in the treated group (16.1 ml/12 hrs) than in the untreated controls (49.8 ml/12 hrs). Gastric juice suppression by roxatidine was 90% in patients with gastric ulcer, 74% in patients with duodenal ulcer, 63% in patients with gastritis, and 70% in patients with no evidence of disease. It is concluded that 150 mg of roxatidine daily would be adequate to treat patients with gastric diseases.
Department of Radiology, Kanto Rosai Hospital, Kawasaki City, Japan.
H
H
Tanioka
A
A
Terahara
Y
Y
Sasaki
D000328:Adult; D005260:Female; D005750:Gastric Juice / Q000378:metabolism*; D005756:Gastritis / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000378:metabolism; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*
D006635:Histamine H2 Antagonists; D010880:Piperidines; C053742:roxatidine acetate